316 related articles for article (PubMed ID: 20622000)
1. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.
Penel N; Le Cesne A; Bui BN; Perol D; Brain EG; Ray-Coquard I; Guillemet C; Chevreau C; Cupissol D; Chabaud S; Jimenez M; Duffaud F; Piperno-Neumann S; Mignot L; Blay JY
Ann Oncol; 2011 Feb; 22(2):452-7. PubMed ID: 20622000
[TBL] [Abstract][Full Text] [Related]
2. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Rauch G; Limprecht R; Sommer M; Dimitrakopoulou-Strauss A; Pilz L; Haller F; Hohenberger P
Eur J Cancer; 2017 May; 76():60-67. PubMed ID: 28282612
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
[TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
Rutkowski P; Van Glabbeke M; Rankin CJ; Ruka W; Rubin BP; Debiec-Rychter M; Lazar A; Gelderblom H; Sciot R; Lopez-Terrada D; Hohenberger P; van Oosterom AT; Schuetze SM; ;
J Clin Oncol; 2010 Apr; 28(10):1772-9. PubMed ID: 20194851
[TBL] [Abstract][Full Text] [Related]
9. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
Ogata K; Mochiki E; Ojima H; Haga N; Fukuchi M; Aihara R; Ando H; Uchida N; Toyomasu Y; Suzuki M; Kimura A; Kogure N; Yokobori T; Ohno T; Kuwano H
J Surg Oncol; 2014 Dec; 110(8):942-6. PubMed ID: 25164620
[TBL] [Abstract][Full Text] [Related]
10. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
Mace J; Sybil Biermann J; Sondak V; McGinn C; Hayes C; Thomas D; Baker L
Cancer; 2002 Dec; 95(11):2373-9. PubMed ID: 12436445
[TBL] [Abstract][Full Text] [Related]
11. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.
Millot F; Baruchel A; Guilhot J; Petit A; Leblanc T; Bertrand Y; Mazingue F; Lutz P; Vérité C; Berthou C; Galambrun C; Bernard F; Yacouben K; Bordigoni P; Edan C; Reguerre Y; Couillault G; Méchinaud F; Cayuela JM; Guilhot F
J Clin Oncol; 2011 Jul; 29(20):2827-32. PubMed ID: 21670449
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.
Frank-Raue K; Fabel M; Delorme S; Haberkorn U; Raue F
Eur J Endocrinol; 2007 Aug; 157(2):215-20. PubMed ID: 17656601
[TBL] [Abstract][Full Text] [Related]
13. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.
Cohen MH; Cortazar P; Justice R; Pazdur R
Oncologist; 2010; 15(3):300-7. PubMed ID: 20200041
[TBL] [Abstract][Full Text] [Related]
14. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors.
Skubitz KM; Manivel JC; Clohisy DR; Frolich JW
Cancer Chemother Pharmacol; 2009 Aug; 64(3):635-40. PubMed ID: 19404642
[TBL] [Abstract][Full Text] [Related]
15. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
Cervantes F; López-Garrido P; Montero MI; Jonte F; Martínez J; Hernández-Boluda JC; Calbacho M; Sureda A; Pérez-Rus G; Nieto JB; Pérez-López C; Román-Gómez J; González M; Pereira A; Colomer D
Haematologica; 2010 Aug; 95(8):1317-24. PubMed ID: 20220063
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.
Chugh R; Wathen JK; Patel SR; Maki RG; Meyers PA; Schuetze SM; Priebat DA; Thomas DG; Jacobson JA; Samuels BL; Benjamin RS; Baker LH;
Clin Cancer Res; 2010 Oct; 16(19):4884-91. PubMed ID: 20724445
[TBL] [Abstract][Full Text] [Related]
17. Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha.
Candelaria M; Arias-Bonfill D; Chávez-Blanco A; Chanona J; Cantú D; Pérez C; Dueñas-González A
Int J Gynecol Cancer; 2009 Dec; 19(9):1632-7. PubMed ID: 19955950
[TBL] [Abstract][Full Text] [Related]
18. Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil.
Silveira CA; Daldegan MB; Ferrari I
Genet Mol Res; 2011 Sep; 10(3):2038-48. PubMed ID: 21968620
[TBL] [Abstract][Full Text] [Related]
19. O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma.
Penel N; Delcambre C; Durando X; Clisant S; Hebbar M; Negrier S; Fournier C; Isambert N; Mascarelli F; Mouriaux F
Invest New Drugs; 2008 Dec; 26(6):561-5. PubMed ID: 18551246
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib.
Kasper B; Dimitrakopoulou-Strauss A; Strauss LG; Hohenberger P
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1876-82. PubMed ID: 20559633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]